Analysts Cut Sun Forecasts After New Halol Site Faults
Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.
Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.